Conditions · Pancreatic cancer
Pancreatic cancer — frontier options in Michigan
30 open options
- TRIALPHASE3RECRUITING
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
Setidegrasib · Oxaliplatin · Leucovorin — 48 sites
- TRIALPHASE2RECRUITING
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
Autogene cevumeran · Atezolizumab · mFOLFIRINOX — 89 sites
- TRIALPHASE2 / PHASE3RECRUITING
Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)
GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT) — 2 sites
- TRIALPHASE1RECRUITING
AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
AVA6103 — 3 sites
- TRIALPHASE1 / PHASE2RECRUITING
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Elironrasib · Daraxonrasib — 55 sites
- EXPANDED ACCESSAVAILABLE
Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma
daraxonrasib — 257 sites
- TRIALPHASE2RECRUITING
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Biospecimen Collection · Computed Tomography · Magnetic Resonance Imaging — 454 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
VS-7375 · Cetuximab · Carboplatin + Pemetrexed + Pembrolizumab — 14 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
MT-4561 — 6 sites
- TRIALPHASE1RECRUITING
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RMC-5127 · daraxonrasib · cetuximab — 9 sites
- TRIALPHASE2RECRUITING
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
Pemigatinib · Computed Tomography (CT) · Magnetic Resonance Imaging — 109 sites
- TRIALPHASE3RECRUITING
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
RYZ101 · Everolimus · Sunitinib — 54 sites
- TRIALPHASE1RECRUITING
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
LY4170156 · bevacizumab · carboplatin — 23 sites
- TRIALPHASE2 / PHASE3RECRUITING
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
SBP-101 · Nab-paclitaxel · Gemcitabine — 93 sites
- TRIALPHASE1RECRUITING
A Study of MGC026 in Participants With Advanced Solid Tumors
MGC026 Dose Escalation · MGC026 Dose for Expansion — 12 sites
- TRIALPHASE1RECRUITING
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
LY4052031 — 39 sites
- TRIALPHASE1RECRUITING
A Study of MGC028 in Participants With Advanced Solid Tumors
MGC028 — 7 sites
- TRIALPHASE1 / PHASE2RECRUITING
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Biospecimen Collection · Dual X-ray Absorptiometry · Tegavivint — 21 sites
- TRIALPHASE2RECRUITING
Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas
Proton Radiation · Capecitabine · Surgical resection — 4 sites
- TRIALPHASE1NOT_YET_RECRUITING
Phase I Open-Label Randomized Multicenter Study of XNW28012 Monotherapy in Metastatic Pancreatic Cancer
XNW28012 — 8 sites
- TRIALPHASE2RECRUITING
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Belzutifan — 84 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
LCB84 · Anti-PD-1 monoclonal antibody — 8 sites
- TRIALPHASE1 / PHASE2RECRUITING
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
64Cu-LNTH-1363S — 5 sites
- TRIALPHASE3RECRUITING
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
Biospecimen Collection · Computed Tomography · Fluorouracil — 274 sites
- TRIALPHASE1RECRUITING
Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy
Capecitabine · Sacituzumab govetican — 1 site
- TRIALPHASE2RECRUITING
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
BAY2927088 — 54 sites
- TRIALPHASE2RECRUITING
Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy
TCMCB07 · Placebo — 26 sites
- TRIALPHASE2 / PHASE3RECRUITING
A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer
OT-101 · mFOLFIRINOX — 2 sites
- TRIALPHASE1RECRUITING
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
LY4337713 — 30 sites
- TRIALPHASE2RECRUITING
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
VS-7375 · cetuximab — 28 sites
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.